Nicholas W Sterling1, Ming Wang1, Lijun Zhang1, Eun-Young Lee1, Guangwei Du1, Mechelle M Lewis1, Martin Styner1, Xuemei Huang2. 1. From the Departments of Neurology (N.W.S., L.Z., E.-Y.L., G.D., M.M.L., X.H.), Public Health Sciences (M.W.), Pharmacology (M.M.L., X.H.), Radiology (X.H.), Neurosurgery (X.H.), and Kinesiology (X.H.), Pennsylvania State University-Milton S. Hershey Medical Center; and Departments of Computer Science and Psychiatry (M.S.), University of North Carolina, Chapel Hill. 2. From the Departments of Neurology (N.W.S., L.Z., E.-Y.L., G.D., M.M.L., X.H.), Public Health Sciences (M.W.), Pharmacology (M.M.L., X.H.), Radiology (X.H.), Neurosurgery (X.H.), and Kinesiology (X.H.), Pennsylvania State University-Milton S. Hershey Medical Center; and Departments of Computer Science and Psychiatry (M.S.), University of North Carolina, Chapel Hill. xuemei@psu.edu.
Abstract
OBJECTIVE: Nigrostriatal terminal losses are known to progress most rapidly in early-stage Parkinson disease (PD) and then plateau, whereas cortical pathology continues and may provide a better marker of PD progression in later stages. We investigated cortical gyrification indices in patients with different durations of PD, since cortical folding may capture complex processes involving transverse forces of neuronal sheets or underlying axonal connectivity. METHODS: Longitudinal cohort structural MRI were obtained at baseline, 18 months, and 36 months from 70 patients with PD without dementia and 70 control participants. Cortical local gyrification index (LGI) was compared between controls and PD subgroups based upon duration of illness (DOI, <1 year [PDE, n = 17], 1-5 years [PDM, n = 19], >5 years [PDL, n = 24]) and adjusted using false discovery rate. Associations between LGI and clinical measurements were assessed using multiple linear regression. Areas having significantly reduced LGI also were analyzed using baseline data from a newly established cohort (PD n = 87, control n = 66) to validate our findings. RESULTS: In the longitudinal cohort, PDL had significantly reduced overall gyrification, and bilaterally in the inferior parietal, postcentral, precentral, superior frontal, and supramarginal areas, compared to controls (p < 0.05). Longitudinally, loss of gyrification was accelerated in PDM participants, compared to controls. LGI showed robust correlations with DOI and also was correlated with PD-related clinical measurements. Similar results were obtained in the validation sample. CONCLUSIONS: Loss of cortical gyrification may be accelerated within the first few years after PD diagnosis, and become particularly prominent in later stages. Thus, it may provide a metric for monitoring progression in vivo.
OBJECTIVE: Nigrostriatal terminal losses are known to progress most rapidly in early-stage Parkinson disease (PD) and then plateau, whereas cortical pathology continues and may provide a better marker of PD progression in later stages. We investigated cortical gyrification indices in patients with different durations of PD, since cortical folding may capture complex processes involving transverse forces of neuronal sheets or underlying axonal connectivity. METHODS: Longitudinal cohort structural MRI were obtained at baseline, 18 months, and 36 months from 70 patients with PD without dementia and 70 control participants. Cortical local gyrification index (LGI) was compared between controls and PD subgroups based upon duration of illness (DOI, <1 year [PDE, n = 17], 1-5 years [PDM, n = 19], >5 years [PDL, n = 24]) and adjusted using false discovery rate. Associations between LGI and clinical measurements were assessed using multiple linear regression. Areas having significantly reduced LGI also were analyzed using baseline data from a newly established cohort (PD n = 87, control n = 66) to validate our findings. RESULTS: In the longitudinal cohort, PDL had significantly reduced overall gyrification, and bilaterally in the inferior parietal, postcentral, precentral, superior frontal, and supramarginal areas, compared to controls (p < 0.05). Longitudinally, loss of gyrification was accelerated in PDM participants, compared to controls. LGI showed robust correlations with DOI and also was correlated with PD-related clinical measurements. Similar results were obtained in the validation sample. CONCLUSIONS: Loss of cortical gyrification may be accelerated within the first few years after PD diagnosis, and become particularly prominent in later stages. Thus, it may provide a metric for monitoring progression in vivo.
Authors: S Orimo; T Uchihara; T Kanazawa; Y Itoh; K Wakabayashi; A Kakita; H Takahashi Journal: Neuropathol Appl Neurobiol Date: 2011-12 Impact factor: 8.090
Authors: Bruno Dubois; David Burn; Christopher Goetz; Dag Aarsland; Richard G Brown; Gerald A Broe; Dennis Dickson; Charles Duyckaerts; Jefferey Cummings; Serge Gauthier; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Yoshikuni Mizuno; Ian G McKeith; C Warren Olanow; Werner Poewe; Cristina Sampaio; Eduardo Tolosa; Murat Emre Journal: Mov Disord Date: 2007-12 Impact factor: 10.338
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Katrina Gwinn; Karen K David; Christine Swanson-Fischer; Roger Albin; Coryse St Hillaire-Clarke; Beth-Anne Sieber; Codrin Lungu; F DuBois Bowman; Roy N Alcalay; Debra Babcock; Ted M Dawson; Richard B Dewey; Tatiana Foroud; Dwight German; Xuemei Huang; Vlad Petyuk; Judith A Potashkin; Rachel Saunders-Pullman; Margaret Sutherland; David R Walt; Andrew B West; Jing Zhang; Alice Chen-Plotkin; Clemens R Scherzer; David E Vaillancourt; Liana S Rosenthal Journal: Biomark Med Date: 2017-06-23 Impact factor: 2.851
Authors: Trina Mitchell; Stéphane Lehéricy; Shannon Y Chiu; Antonio P Strafella; A Jon Stoessl; David E Vaillancourt Journal: JAMA Neurol Date: 2021-10-01 Impact factor: 29.907
Authors: Ming Wang; Zheng Li; Eun Young Lee; Mechelle M Lewis; Lijun Zhang; Nicholas W Sterling; Daymond Wagner; Paul Eslinger; Guangwei Du; Xuemei Huang Journal: BMC Med Res Methodol Date: 2017-09-25 Impact factor: 4.615